

europaean journal of gynaecological oncology

an International Journal

Editors-in-Chief

A. Onnis **P. Bószé**
Montréal (Canada) Budapest (Hungary)

Associate Editor

M. Marchetti
Montréal (Canada)

Assistant Editor

J. Wilson
San Diego - CA (USA)

Editorial Board

Allen H.H., <i>London, Ontario (Canada)</i>	Geisler H.E., <i>Indianapolis, IN (USA)</i>	Menczer J., <i>Savyon (Israel)</i>
Anteby S.O., <i>Jerusalem (Israel)</i>	Gerbaulet A., <i>Villejuif (France)</i>	Monsonogo J., <i>Paris (France)</i>
Audet-Lapointe P., <i>Montreal (Canada)</i>	Gorins A., <i>Paris (France)</i>	Pinotti A., <i>São Paulo (Brazil)</i>
Ayhan A., <i>Ankara (Turkey)</i>	Heintz A.P.M., <i>Utrecht (The Netherlands)</i>	Piura B., <i>Beer Sheva (Israel)</i>
Balat O., <i>Graziantep (Turkey)</i>	Ioannidou-Mouzaka L., <i>Athens (Greece)</i>	Piver S.M., <i>Buffalo, NY (USA)</i>
Barber H.K., <i>New York, NY (USA)</i>	Jordan J.A., <i>Birmingham, England (UK)</i>	Rakar S., <i>Ljubljana (Slovenia)</i>
Basta A., <i>Krakow (Poland)</i>	Karseladze A.I., <i>Moscow (Russia)</i>	Raju K.S., <i>London, England (UK)</i>
Bender H.C., <i>Dusseldorf (Germany)</i>	Klastersky J., <i>Bruxelles (Belgium)</i>	Shepherd J.H., <i>London, England (UK)</i>
Benedetti Panici P.L., <i>Rome (Italy)</i>	Kubista E., <i>Vienna (Austria)</i>	Stelmachów J., <i>Warsaw (Poland)</i>
Charkviani T., <i>Tbilisi (Georgia)</i>	Kudelka A.P., <i>Houston, TX (USA)</i>	Tjalma W., <i>Antwerpen (Belgium)</i>
De Oliveira C.F., <i>Coimbra (Portugal)</i>	Maggino T., <i>Padua (Italy)</i>	Ungár L., <i>Budapest (Hungary)</i>
Dexeus S. Jr., <i>Barcelona (Spain)</i>	Markowska J., <i>Poznan (Poland)</i>	Vermorken J.B., <i>Edegem (Belgium)</i>
Di Paola G.R., <i>Buenos Aires (Argentina)</i>	Marth C., <i>Innsbruck (Austria)</i>	Vírtej P., <i>Bucharest (Romania)</i>
Di Re F., <i>Milan (Italy)</i>	Massuger Leon F.A.G., <i>Nijmegen (The Netherlands)</i>	Wang P.-H., <i>Taipei (Taiwan)</i>
Di Saia P., <i>Orange, CA (USA)</i>		Winter R., <i>Graz (Austria)</i>
Fuller A.F. Jr., <i>Boston, MA (USA)</i>		Yokoyama Y., <i>Hirosaki (Japan)</i>

Publishing Organization (M. Morsani):

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

Editorial Office (M. Critelli):

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

European Journal of Gynaecological Oncology

www.irog.net

General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.

COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mggroup-online.com - www.irog.net

RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

Claims for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

European Journal of Gynaecological Oncology

www.irog.net

Instructions to Authors

SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three **manuscripts** typed and double spaced should be submitted by mail (not by email) **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the **Corresponding Author**, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the **title page** (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: **Summary** (purpose of investigation, methods, results, conclusion - about 150 words), **Key words**, **Content** (a 20-word summary), **Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement** (if any), **References, Tables, Legends**.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS

The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

DISTINGUISHED EXPERT SERIES

- The sentinel node biopsy in patients with breast cancer; many controversies remain** 321
 M.C. Van Rijk, O.E. Nieweg, H.S.A. Oldenburg, E.J.Th. Rutgers, B.B.B. Kroon - *Amsterdam, THE NETHERLANDS*
 In this review several aspects regarding the controversies about unsolved aspects of the sentinel node biopsy in breast cancer are discussed.
- International Society for the Study of Vulvovaginal Disease - Founders lecture** 329
 G.R. di Paola - *Buenos Aires, ARGENTINA*
 Thirty-five years of the International Society for the study of vulvovaginal disease were relived.
- Vaccination against human genital papillomaviruses. More than a hypothesis** 337
 G. De Palo, L. Mariani - *Rome, ITALY*
 Vaccination against HPV has been proposed. The results of HPV clinical studies suggest that it will be possible to develop an effective vaccine, nevertheless several points need further investigation.

ORIGINAL ARTICLES

- Jun and Fos family protein expression in human breast cancer: Correlation of protein expression and clinicopathological parameters** 345
 S. Langer, C.F. Singer, G. Hudelist, B. Dampier, K. Kaserer, U. Vinatzer, H. Pehamberger, C. Zielinski, E. Kubista, M. Schreiber - *Vienna, AUSTRIA*
 An important role for JunB and Fra1 in the biological behavior of malignant breast tumors is presented.
- Serum CA125 level modifications in women undergoing repeated IVF cycles** 353
 D. Caserta, R. Marci, C. Tatone, V. Dolo, E. Di Roma, A. Fazi, M. Moscarini - *L'Aquila, ITALY*
 Serum CA125 modifications and IVF outcome in women undergoing repeated cycles are described.
- Preliminary results of mitomycin C local application as post-treatment prevention of vaginal radiation-induced morbidity in women with cervical cancer** 356
 J. Sobotkowski, J. Markowska, J. Fijuth, A. Pietraszek - *Lodz, POLAND*
 To avoid vaginal fibrosis mitomycin C solution was applied locally to patients. Analysis of material showed that this procedure can potentially diminish fibrotic changes after radiotherapy for cervical cancer.
- Sentinel node detection with the blue dye technique in early cervical cancer** 359
 V. Schwendinger, E. Müller-Holzner, A.G. Zeimet, C. Marth - *Innsbruck, AUSTRIA*
 A retrospective study of sentinel node detection with the blue dye technique in women with early cervical cancer is presented.
- VEGF induces phosphorylation of STAT3 through binding VEGFR2 in ovarian carcinoma cells in vitro** 363
 W. Lu, H. Chen, F. Ye, F. Wang, X. Xie - *Hangzhou, CHINA*
 STAT3 activation induced by VEGF in ovarian carcinoma cells was investigated.
- Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma** 370
 C-M. Juang, M-S. Yen, H-C. Horng, N-F. Twu, H-C. Yu, W-L. Hsu - *Taipei, TAIWAN*
 This report investigated preoperative differentiation between uterine leiomyoma and uterine leiomyosarcoma.
- Does shifting a physician payment system shift physician priorities? A multi-site evaluation of an alternative payment plan (APP) for gynecologic oncologists in Ontario** 375
 L. Elit, J. Cosby - *Ontario, CANADA*
 A study attempting to understand how changing the mode of reimbursement alters physician behavior from the physician's perspective was undertaken.
- Studies on leptin and leptin receptor gene expression in myometrium and uterine myomas of GnRH analogue-treated women** 379
 A. Markowska, M. Rucinski, K. Drews, L.K. Malendowicz - *Poznan, POLAND*
 The results of the study suggest that no direct or immediate inter-relationship exists between expression of leptin genes in uterine myomas on one hand and estrogen, progesterone and leptin levels in the blood on the other.

A therapeutic algorithm for early-stage endometrial cancer: Indications, patient selection, and feasibility	385
E.M. Messalli, C. Scaffa, G. Mainini, M. Rotondi, A. Cafiero, L. Cobellis - <i>Naples, ITALY</i>	
A therapeutic algorithm for early-stage endometrial cancer was studied in order to achieve the best outcome for patients.	
Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium	389
T. Cirpan, M.C. Terek, L. Mgoyi, O. Zekioglu, O. Iscan, A. Ozsaran - <i>Izmir, TURKEY</i>	
The aim of this study was to reclassify endometrial hyperplasia cases and examine PTEN protein immunoreactivity compared to cases with endometrial adenocarcinoma and proliferative endometrium.	
Is dosage of hormone replacement therapy related with endometrial polyp formation?	393
G. Iatrakis, S. Zervoudis, E. Antoniou, C. Tsonis, A. Pavlou, G. Kourounis, K. Siskos - <i>Patras, GREECE</i>	
The effect of different doses of hormone replacement therapy on endometrial polyp formation was evaluated.	
Primary yolk sac tumor (endodermal sinus tumor) of the vulva: case report and review of the literature	395
A. Basgul, H. Gokaslan, Z.N. Kavak, F.T. Eren, N. Bozkurt - <i>Istanbul, TURKEY</i>	
The tenth case of endodermal sinus tumor of the vulva in a 32-year-old white virgin is reported.	
Women younger than 50 years with endometrial cancer	399
G. Iatrakis, S. Zervoudis, A. Saviolakis, M. Troulos, E. Antoniou, A. Sarantaki, K. Lykeridou, G. Kourounis - <i>Athens, GREECE</i>	
This study evaluated whether known risk factors for endometrial cancer in menopausal women are also related to endometrial cancer in younger ages.	
Impact of morbid obesity in surgical management of endometrial cancer: surgical morbidity, clinical and pathological aspects	401
S. Erkanli, F. Kayaselçuk, T. Bagis, E. Kuşçu - <i>Adana, TURKEY</i>	
The effect of body mass index (BMI) on clinical, surgical, and pathologic features, and surgical morbidity in the management of patients with endometrial cancer was evaluated.	
<i>Chlamydia trachomatis</i> and <i>herpes simplex virus 2</i> infection in vulvar intraepithelial neoplasia associated with human papillomavirus	405
A. Kwaśniewska, E. Korobowicz, J. Visconti, M. Zdunek, M. Szymański, A. Goździcka-Jozefiak - <i>Poznan, POLAND</i>	
Archival diagnostic phase tissue specimens from 41 cases of vulvar intraepithelial neoplasia III were identified. The lesion characteristics were examined in comparison with the presence of HPV DNA, HSV-2 and <i>Chlamydia trachomatis</i> . No correlation was found between the frequency of occurrence of HPV and HSV-2 and HPV and <i>Chlamydia trachomatis</i> in either group.	
Endometrial carcinoma and hormonal disturbances in middle-aged women - an overview	409
L. Gojnic, V. Dugalic, V. Jeremic, D. Filimonovic, Lj. Arsenijevic - <i>Belgrade, SERBIA AND MONTENEGRO</i>	
Patients at two institutions in Belgrade were examined. In 27% of the cases (310 patients), positive findings of malignancy were found. Out of this number, 54% of the cases were endometrial adenocarcinoma Stage Ib, 34% were Stage Ib and 12% were Stage IIIa.	
Receptor modifications in vulvar dystrophies before and after treatment with topical hormones: comparison between the dextran-charcoal technique and immunohistochemical evaluation	411
G. Capobianco, S. Dessole, A. Cossu, V. Marras, G.B. Meloni, S. Mesina, P. Demurtas, P.L. Cherchi	
Testosterone propionate 2% is efficacious in vulvar dystrophies inducing an increase of trophism due to the increase of estrogen receptors.	
CASE REPORTS	
The management of ectopic breast cancer - Case Report	414
W.A.A. Tjalma, L.L.C. Senten - <i>Edegem, BELGIUM</i>	
All breast tissue, non-ectopic and ectopic, is susceptible to pathological conditions and should therefore be approached similarly.	
Serous cystadenoma of borderline malignancy arising in a parovarian paramesonephric cyst	417
F. Puig, C. Crespo, I. Marquina - <i>Zaragoza, SPAIN</i>	
A rare case of serous cystadenoma of borderline malignancy arising in a paraovarian paramesonephric cyst is reported.	
A case of cellulitis that complicated lymphedema of the lower limb and produced systemic inflammatory response syndrome (SIRS)	419
A. Kasai-Sakamoto, Y. Yokoyama, H. Mizunuma - <i>Aomori, JAPAN</i>	
A case of lymphedema of the lower limb complicated by severe cellulitis with systemic inflammatory response syndrome in which a split-thickness graft was required for a complete cure is reported.	

Colorectal cancer emergencies during pregnancy - Case Reports	412
T. Theodosopoulos, A. Marinis, N. Dafnios, L. Samanideis, D. Voros, J. Vassiliou, V. Smyrniotis - <i>Athens, GREECE</i> Treatment of colorectal cancer emergencies during pregnancy depends on gestational age, location of the tumor and maternal preferences.	
Synchronous primary cancers of the endometrium and ovary: a case report	425
K. Güzin, C. Tekcan, M.M. Naki, S. Kayatas, E. Zemheri, F. Kanadıkırık, S. Berkman - <i>Istanbul, TURKEY</i> A case of synchronous primary cancers of the endometrium and ovary is reported and the management discussed.	
Abdominal apoplexy associated with the levonorgestrel intrauterine system - case report	429
W.A.A. Tjalma - <i>Edegem, BELGIUM</i> A case of abdominal apoplexy in a patient using a levonorgestrel intrauterine system is reported.	
Endometrial adenocarcinoma after endometrial ablation. A case report	432
A. Areia, M. Branco, C. Frutuoso, C.F. de Oliveira - <i>Coimbra, PORTUGAL</i> A case of endometrial adenocarcinoma after endometrial ablation is presented with emphasis on the importance of close surveillance of these patients.	
Synchronous primary endometrial and ovarian cancers: a case report	434
G. Decavalas, G. Adonakis, G. Androutsopoulos, P. Gkogkos, D. Koumoundourou, P. Ravazoula, G. Kourounis - <i>Rion, GREECE</i> A case of synchronous primary endometrial and ovarian cancers is presented.	
Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis - Case report	437
Y. Yokoyama, M. Futagami, T. Higuchi, H. Mizunuma - <i>Hirosaki, JAPAN</i> The pharmacokinetics of paclitaxel and carboplatin in a FIGO Stage IIIb ovarian cancer patient with hemodialysis-dependent chronic renal failure were examined.	
Sentinel node biopsy helps to diagnose spread of endometrial cancer. A case report	440
A.S. Bats, D. Clément, M.A. Le Frère-Belda, F. Larousserie, M.A. Collignon, C. Hignette, F. Lécuru - <i>Paris, FRANCE</i> Sentinel node biopsy improves the accuracy of nodal staging during the surgical management of early endometrial cancer.	
Solitary ovarian metastasis from cutaneous melanoma - Case report	443
K. Jeremić, M. Berisavac, R. Argirović, M. Gojnić, V. Bošković, V. Milenković, T. Mostić - <i>Belgrade, SERBIA AND MONTENEGRO</i> A 47-year-old patient five years after malignant melanoma of the left leg developed ovarian metastasis.	

ERRATA - CORRIGE

Double laparotomy wound recurrence of endometrial carcinoma - G.C. Balbi, A. Cardone, A. Monteverde, M. Passaro, L. Montone¹, R. Rossiello¹, S. Visconti, M. Battisti, E. Cassese, I. Landino - *Naples, ITALY*
Department of Obstetrics and Gynecology, ¹Department of Pathological Anatomy, "L. Armani" Second University of Naples (SUN), Naples (Italy)
Vol. XXVII, n. 3, 2006, page 307

Errata: G.C. Balbi, A. Cardone, A. Monteverde, M. Passaro, L. Montone¹, R. Rossiello¹, S. Visconti, M. Battisti, E. Cassese, I. Landino

Corrige: G.C. Balbi, A. Cardone, A. Monteverde, M. Passaro, L. Montone¹, R. Rossiello¹, S. Visconti, M. Battista, E. Cassese, I. Landino

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY

Vol. XXVII, Number 4, 2006

ISSN: 0392-2936

I.R.O.G. CANADA, Inc.

Publisher's office: 4900 Côte St. Luc - Apt. 212 - Montréal, Québec H3W 2H3 (Canada) - Tél.: (514) 4893640-4893242 - Fax: (514) 4854513

E-mail: canlux@mgroup-online.com - www.irog.net

ALL RIGHTS RESERVED

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopies, recordings, nor any information storage and retrieval system without written permission from the copyright owner.

Printed in Italy